InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV [Forbes]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Forbes
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here Nicole Gaudelli, entrepreneur-in-residence in life sciences, GV. A s a postdoctoral researcher at the Broad Institute of MIT and Harvard, Nicole Gaudelli was the co-inventor of a breakthrough in gene editing: the ability to target a single misspelling in DNA code. This invention, known as base editing , is a further advancement of the Nobel Prize-winning Crispr technology and has the potential to cure thousands of rare diseases caused by point mutations. She then joined Beam Therapeutics to, in her words, “make the dream of having that technology become a reality for patients really materialize.” With clinical trials now underway at Beam for patients with sickle cell disease and a rare liver disease known as alpha-1 antitrypsin deficiency, Gaudelli hopes to embark on a new journey from the bench to the bedside. Today GV (formerly known as Google Ventures) announced Gaudelli will be
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects [Seeking Alpha]Seeking Alpha
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.MarketBeat
- Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $57.00 price target on the stock.MarketBeat
BEAM
Earnings
- 2/27/24 - Beat
BEAM
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- BEAM's page on the SEC website